A randomized controlled trial examining the effects of intranasal oxytocin on alcohol craving and intimate partner aggression among couples.
Aggression
Alcohol use disorder
Couples
Craving
Intimate partner violence
Oxytocin
Journal
Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
17
01
2022
revised:
01
06
2022
accepted:
06
06
2022
pubmed:
17
6
2022
medline:
27
7
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
While alcohol use disorder (AUD) is a well-established risk factor for intimate partner aggression (IPA), effective treatments for co-occurring AUD and IPA (AUD/IPA) are lacking. Oxytocin is one promising pharmacological candidate for AUD/IPA given its potential to modulate social behavior and attenuate alcohol use. However, emerging data suggests that oxytocin's prosocial effects are inconsistent, and a small number of studies have also found that oxytocin might have the potential to be aggressogenic. No studies have directly examined the impact of oxytocin on alcohol- or IPA-related outcomes in a dyadic context. The goal of this double-blind, randomized, and placebo-controlled trial was to examine the effects of a single dose of intranasal oxytocin (40 international units) on cue-induced alcohol craving, subjective aggression, laboratory task-based IPA, and cortisol reactivity in a sample of 100 couples (N = 200 individuals) with AUD and physical IPA in their current relationship. There were no statistically significant differences between the oxytocin and placebo conditions for any of the primary outcomes. Findings suggest that a single dose of intranasal oxytocin was not efficacious in mitigating alcohol craving or aggression in this sample. Although hypotheses were not supported, the findings provide important evidence that oxytocin was not aggressogenic in this high-risk sample. Future research investigating dispositional and contextual moderators of oxytocin response in addition to the therapeutic effects of more intensive oxytocin dosing or administration strategies on alcohol craving and aggression is warranted.
Sections du résumé
BACKGROUND
While alcohol use disorder (AUD) is a well-established risk factor for intimate partner aggression (IPA), effective treatments for co-occurring AUD and IPA (AUD/IPA) are lacking. Oxytocin is one promising pharmacological candidate for AUD/IPA given its potential to modulate social behavior and attenuate alcohol use. However, emerging data suggests that oxytocin's prosocial effects are inconsistent, and a small number of studies have also found that oxytocin might have the potential to be aggressogenic. No studies have directly examined the impact of oxytocin on alcohol- or IPA-related outcomes in a dyadic context.
METHODS
The goal of this double-blind, randomized, and placebo-controlled trial was to examine the effects of a single dose of intranasal oxytocin (40 international units) on cue-induced alcohol craving, subjective aggression, laboratory task-based IPA, and cortisol reactivity in a sample of 100 couples (N = 200 individuals) with AUD and physical IPA in their current relationship.
RESULTS
There were no statistically significant differences between the oxytocin and placebo conditions for any of the primary outcomes.
CONCLUSIONS
Findings suggest that a single dose of intranasal oxytocin was not efficacious in mitigating alcohol craving or aggression in this sample. Although hypotheses were not supported, the findings provide important evidence that oxytocin was not aggressogenic in this high-risk sample. Future research investigating dispositional and contextual moderators of oxytocin response in addition to the therapeutic effects of more intensive oxytocin dosing or administration strategies on alcohol craving and aggression is warranted.
Identifiants
pubmed: 35709548
pii: S0022-3956(22)00308-9
doi: 10.1016/j.jpsychires.2022.06.011
pmc: PMC9308670
mid: NIHMS1814531
pii:
doi:
Substances chimiques
Ethanol
3K9958V90M
Oxytocin
50-56-6
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-24Subventions
Organisme : NIAAA NIH HHS
ID : K23 AA023845
Pays : United States
Organisme : NIAAA NIH HHS
ID : K23 AA027307
Pays : United States
Organisme : NIAAA NIH HHS
ID : T32 AA007474
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Références
J Addict Med. 2016 May-Jun;10(3):182-9
pubmed: 27159342
Neurosci Biobehav Rev. 2021 Aug;127:852-864
pubmed: 34102150
Harv Rev Psychiatry. 2010 Jan-Feb;18(1):1-21
pubmed: 20047458
Aggress Behav. 2008 Mar-Apr;34(2):214-29
pubmed: 17894385
Psychoneuroendocrinology. 2019 Aug;106:147-154
pubmed: 30981088
Horm Behav. 2019 Feb;108:20-29
pubmed: 30593782
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Trends Cogn Sci. 2011 Jul;15(7):301-9
pubmed: 21696997
Mol Psychiatry. 2021 Jan;26(1):80-91
pubmed: 32807845
J Consult Clin Psychol. 2003 Aug;71(4):812-20
pubmed: 12924686
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
J Stud Alcohol Drugs. 2011 Jan;72(1):34-43
pubmed: 21138709
Curr Top Behav Neurosci. 2018;35:175-192
pubmed: 28864975
Psychoneuroendocrinology. 2018 Jul;93:124-132
pubmed: 29727809
Biol Psychiatry. 2016 Feb 1;79(3):251-7
pubmed: 26210057
Br J Addict. 1986 Oct;81(5):655-60
pubmed: 3466632
Brain Res. 2014 Sep 11;1580:69-77
pubmed: 24239931
Psychol Addict Behav. 2005 Mar;19(1):35-42
pubmed: 15783276
Am J Prev Med. 2006 Jun;30(6):458-66
pubmed: 16704938
Am J Prev Med. 2018 Oct;55(4):433-444
pubmed: 30166082
Aggress Behav. 2022 May;48(3):279-289
pubmed: 34608639
Curr Treat Options Psychiatry. 2019 Jun;6(2):132-142
pubmed: 31763133
Neuropharmacology. 2020 Jul;171:108091
pubmed: 32304701
J Trauma Stress. 2004 Oct;17(5):413-21
pubmed: 15633920
Nat Commun. 2020 Jun 3;11(1):2783
pubmed: 32494001
Alcohol Clin Exp Res. 2013 Mar;37(3):484-9
pubmed: 23025690
J Clin Psychiatry. 2011 Jan;72(1):60-5
pubmed: 20673556
Chronic Stress (Thousand Oaks). 2017 Feb;1:
pubmed: 28649672
J Interpers Violence. 2011 May;26(8):1503-23
pubmed: 20522883
Front Psychiatry. 2013 Aug 01;4:72
pubmed: 23914176
Psychoneuroendocrinology. 2014 Nov;49:161-70
pubmed: 25086828
J Interpers Violence. 2003 Jul;18(7):735-43
pubmed: 14675506
Trauma Violence Abuse. 2016 Dec;17(5):585-600
pubmed: 25979872
J Interpers Violence. 2021 Jun;36(11-12):NP6040-NP6064
pubmed: 30453802
Lancet. 2008 Apr 5;371(9619):1165-72
pubmed: 18395577
Psychopharmacology (Berl). 2019 Sep;236(9):2613-2622
pubmed: 30923836
Nature. 2005 Jun 2;435(7042):673-6
pubmed: 15931222
PLoS Biol. 2019 Apr 16;17(4):e2006421
pubmed: 30990816
Violence Vict. 2000 Summer;15(2):137-60
pubmed: 11108498
Alcohol Clin Exp Res. 2018 Sep;42(9):1725-1734
pubmed: 29917245
Violence Against Women. 2015 Aug;21(8):939-57
pubmed: 26059921
J Stud Alcohol Drugs. 2017 Mar;78(2):213-221
pubmed: 28317501
Psychol Addict Behav. 2014 Sep;28(3):780-9
pubmed: 24128287
Eur Neuropsychopharmacol. 2019 Dec;29(2):266-277
pubmed: 30554861
Neurosci Biobehav Rev. 2020 Jan;108:1-23
pubmed: 31647964
J Abnorm Psychol. 1987 May;96(2):122-6
pubmed: 3584660
J Consult Clin Psychol. 2003 Feb;71(1):92-102
pubmed: 12602429
Biol Psychiatry. 2016 Feb 1;79(3):243-50
pubmed: 26049207
Brain Res. 2020 Jun 1;1736:146761
pubmed: 32142721
Ther Deliv. 2018 Jul;9(7):515-525
pubmed: 29943688
Horm Behav. 2016 Apr;80:125-131
pubmed: 26862988
Behav Pharmacol. 2016 Dec;27(8):640-648
pubmed: 27603752
Biol Psychiatry. 2016 Feb 1;79(3):194-202
pubmed: 26321019
Soc Psychiatry Psychiatr Epidemiol. 2011 Sep;46(9):843-52
pubmed: 20582398
Psychol Addict Behav. 2012 Jun;26(2):236-45
pubmed: 21823768
Int J Pharm. 2018 Sep 5;548(1):698-706
pubmed: 30031864
Curr Top Behav Neurosci. 2018;35:559-590
pubmed: 28812273
Trauma Violence Abuse. 2016 Dec;17(5):520-531
pubmed: 26009568
PLoS One. 2011;6(11):e27237
pubmed: 22110618
Br J Addict. 1989 Nov;84(11):1353-7
pubmed: 2597811
Int J Environ Res Public Health. 2016 Mar 31;13(4):394
pubmed: 27043602
Physiol Behav. 2017 Oct 1;179:411-421
pubmed: 28716609
Addiction. 2013 Aug;108(8):1376-84
pubmed: 23414253
Drug Alcohol Depend. 2019 Apr 1;197:95-101
pubmed: 30784955
Alcohol Alcohol. 2021 Aug 30;56(5):565-572
pubmed: 33352584
CNS Drugs. 2016 Feb;30(2):109-23
pubmed: 26932552
Psychol Addict Behav. 2014 Mar;28(1):127-38
pubmed: 24341618
Cell Tissue Res. 2019 Jan;375(1):287-293
pubmed: 30535799
J Pers. 1967 Jun;35(2):297-310
pubmed: 6059850
Violence Against Women. 2008 Feb;14(2):158-84
pubmed: 18212339
Horm Behav. 2012 Mar;61(3):331-9
pubmed: 22198308
Pharmacol Biochem Behav. 2016 Jan;140:27-32
pubmed: 26519603
J Consult Clin Psychol. 2009 Dec;77(6):1136-46
pubmed: 19968389
J Subst Abuse Treat. 2010 Apr;38(3):231-44
pubmed: 20129753
Psychoneuroendocrinology. 2013 May;38(5):612-25
pubmed: 23265311
Am J Prev Med. 2008 Feb;34(2):112-8
pubmed: 18201640
Alcohol Clin Exp Res. 2019 Dec;43(12):2627-2636
pubmed: 31610033
Drug Alcohol Depend. 2010 Dec 1;112(3):194-200
pubmed: 20667666
Clin Psychol Rev. 2005 Feb;25(2):119-52
pubmed: 15642644
Int Rev Neurobiol. 2017;136:239-274
pubmed: 29056153
Int J Psychophysiol. 2019 Feb;136:15-21
pubmed: 30144492
Psychoneuroendocrinology. 2019 Oct;108:172-181
pubmed: 31374475
Drug Alcohol Rev. 2017 Jan;36(1):7-9
pubmed: 27305859
J Subst Abuse Treat. 2018 Jun;89:11-19
pubmed: 29706170
PLoS One. 2007 Nov 07;2(11):e1128
pubmed: 17987115
Public Health Rep. 2006 Jul-Aug;121(4):382-92
pubmed: 16827439
J Interpers Violence. 2009 Aug;24(8):1398-417
pubmed: 18718882
Clin Psychol Sci. 2021 May 1;9(3):385-402
pubmed: 34194870
Alcohol Clin Exp Res. 2017 May;41(5):955-964
pubmed: 28212464